-
- News
- Books
Featured Books
- smt007 Magazine
Latest Issues
Current IssueComing to Terms With AI
In this issue, we examine the profound effect artificial intelligence and machine learning are having on manufacturing and business processes. We follow technology, innovation, and money as automation becomes the new key indicator of growth in our industry.
Box Build
One trend is to add box build and final assembly to your product offering. In this issue, we explore the opportunities and risks of adding system assembly to your service portfolio.
IPC APEX EXPO 2024 Pre-show
This month’s issue devotes its pages to a comprehensive preview of the IPC APEX EXPO 2024 event. Whether your role is technical or business, if you're new-to-the-industry or seasoned veteran, you'll find value throughout this program.
- Articles
- Columns
Search Console
- Links
- Events
||| MENU - smt007 Magazine
Internet of Body: The Next Big Thing for Medical
December 18, 2018 | Nolan Johnson, I-Connect007Estimated reading time: 14 minutes
The second one is the kids. I like to know what my monkeys are doing and if they are fine. The problem with this thing is that it opens a new era of privacy. It’s a new meaning because you can be hacked. Two weeks ago, there was a Bloomberg Businessweek magazine story with what happened to Apple and Amazon, and that’s another story. Now we are overwhelmed because somebody can find these things out about you. If not for bad reasons—for lack of better words—then for life insurance. You have your whole life in a data center somewhere.
There is still time until this becomes a reality. I’m still concerned about my privacy. I’m not doing anything special or wrong, but I’m still concerned. If I look at my daughters, they don’t care; they post everything everywhere—it doesn’t matter. With this approach, if you give it to kids first, they will grow up and, as adults, will say, “Sure. I’d like to know what happened to my heartbeat in the last 24 hours.” It’s another approach.
Johnson: Not only do we have the possibility of invasiveness around data privacy, but IoB starts to touch on a number of different ways of connecting to the body.
Botos: IoB would become successful the moment you forget you have that attachment. Today, it’s still bulky. You still have to put it on, pull it off at night, and eventually charge it. That is still a threshold that many people have to go above or surpass to accept the technology.
The moment it touched your skin, like a sticker, you could forget about it. You could have it there for weeks, months, or even more, and you wouldn’t have to do anything. You could shower and maybe even swim. That will be a true application for IoB.
Johnson: Do you see IoB moving into implantables?
Botos: Yes. It’s already there.
Johnson: I could easily see a pacemaker doing something like that or an implantable blood sugar monitor.
Botos: Yes. The other class I was talking about besides patches is implantables. I saw it last year at the Wearable Technologies Conference in San Francisco where you could have a glass-based encapsulated pill if you want. It’s a near field communication (NFC) tag that you put under your skin, and from that moment, you can start paying with your hand. You can identify yourself to a tag or a door: “Yes, I am Titu. Here I am.” That’s a completely different class. It has a higher class in the medical industry because it has to survive inside your body and should have as little of an effect on your body as possible. The first implant I saw was encapsulated in medical-grade sterile glass.
The other class of IoB devices would be the ingestible ones. You swallow it as a pill, and it has two purposes. First, it’s sensor-based as in it goes, stays in your body for about 24 hours or so, and it collects data as it travels through your digestive tract. You have a receiver on your body somewhere very close because the energy is low like a patch. It transmits that, and when it goes out, it’s basically disposable.
The other scope for this digestible would be to deliver drugs to the right place. Yes, invasively entering the bloodstream is one way—the old way; for example, with something like insulin, we cannot have it as a pill. There have been hundreds of trials where they try to convert insulin into a pill so you can take a pill instead of taking a shot every time you need it. It’s much easier to swallow, but it’s proven that the digestive tract is breaking the insulin into pieces, so that is not the drug anymore.
The point is to have a vehicle that will deliver that insulin intact, so it can do what it was meant to do. That would help, but recognize that it’s a third class. We hope blind people will start to see one day. We have a project in our labs, but it’s still far away from taking somebody from the street and having them regain their vision the next day—that day is still very, very far off.
Johnson: What are some of your customers’ biggest challenges regarding FDA approvals? Do you have any advice for design teams looking at starting to do a medical device around this technology?
Botos: Go with a team that has been doing that for a while because there are a few hoops you have to jump through that can be costly if you don’t know how to approach them.
Johnson: Give me an example.
Page 2 of 3
Suggested Items
I-Connect007 Editor’s Choice: Five Must-Reads for the Week
05/03/2024 | Nolan Johnson, I-Connect007This week’s most important news is strategic—and telling. When one puts together the IPC industry reports, we simply have to include the recent conversation with Shawn DuBravac and Tom Kastner. On the design side, check out the latest “On The Line With…” podcast featuring Brad Griffin from Cadence Design Systems, discussing SI and PI in the realm of intelligent system design.
Synopsys, Samsung Electronics Collaborate to Achieve First Production Tapeout of Flagship Mobile CPU
05/03/2024 | PRNewswireSynopsys, Inc. announced that Samsung Electronics has achieved successful production tapeout for its high-performance mobile SoC design, including flagship CPUs and GPUs, with 300MHz higher performance using Synopsys.ai™ full stack AI-driven EDA suite and a broad portfolio of Synopsys IP on Samsung Foundry's latest Gate-All-Around (GAA) process technologies.
Altair Acquires Research in Flight, Forging a New Path for Aerodynamic Analysis
05/03/2024 | AltairAltair a global leader in computational intelligence, announced it has acquired Research in Flight, maker of FlightStream®, which provides computational fluid dynamics (CFD) software with a large footprint in the aerospace and defense sector and a growing presence in marine, energy, turbomachinery, and automotive applications.
Real Time with… IPC APEX EXPO 2024: Software Solutions for Circuit Board Challenges
05/03/2024 | Real Time with...IPC APEX EXPONolan Johnson speaks with Will Webb from Aster Technologies about their software solutions for design teams, manufacturing, test engineers, and process engineers. Aster's software addresses the increasing complexities of circuit boards and the need for alternative testing methods.
Real Time with… IPC APEX EXPO 2024: My Role as a Technology Solutions Director
05/02/2024 | Real Time with...IPC APEX EXPOPeter Tranitz, senior director of technology solutions at IPC, shares insights into his role as the design initiative lead. He details his advocacy work, industry support, and the responsibilities of the design initiative committee. The conversation also covers the revamping of standards, the IPC Design Competition, and the implementation of design rules in software tools.